Integrin β6 Activators
The chemical class of Integrin β6 activators illuminates a fascinating interplay between diverse compounds and the activation of Integrin β6, a crucial player in cellular adhesion, migration, and tissue homeostasis. Despite their primary roles as inhibitors, these compounds exert their effects indirectly, unveiling a complex network of signaling pathways that converge on Integrin β6 activation. One notable member of this chemical class is Cilengitide, an integrin inhibitor that indirectly activates Integrin β6 by disrupting integrin signaling. This disruption enhances Integrin β6 activation, influencing cellular adhesion and migration within the extracellular matrix. Similarly, E7820, a fibroblast growth factor receptor (FGFR) inhibitor, indirectly activates Integrin β6 by modulating downstream FGFR signaling. This modulation highlights the interconnectedness of various signaling pathways in promoting Integrin β6-mediated processes, such as angiogenesis and tissue remodeling.
The intricacies of Integrin β6 activation are further elucidated by compounds like Fasentin and Tanshinone IIA. Fasentin, a Rac1 inhibitor, indirectly activates Integrin β6 by affecting Rac1-dependent pathways, impacting cellular adhesion, migration, and invasion in the context of cancer progression. Tanshinone IIA, a STAT3 inhibitor, indirectly activates Integrin β6 by modulating STAT3 signaling, revealing a broader regulatory network that influences inflammation and tissue repair. Moreover, the class includes Zoledronic acid, a bisphosphonate, which indirectly activates Integrin β6 through its impact on the mevalonate pathway. This modulation suggests a link between lipid metabolism and Integrin β6-mediated cellular processes, such as adhesion and migration. In conclusion, Integrin β6 activators represent a sophisticated repertoire of compounds that intricately modulate the activation of Integrin β6. Understanding the nuances of these chemical interactions provides insights into the complex web of signaling cascades orchestrating cellular adhesion, migration, and tissue homeostasis, laying the groundwork for further exploration of potential interventions and a deeper comprehension of matrix-mediated cellular dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Cilengitide, an integrin inhibitor, indirectly activates Integrin β6. By blocking integrin signaling, Cilengitide disrupts downstream events, leading to enhanced Integrin β6 activation and its role in cellular adhesion and migration within the extracellular matrix. | ||||||
E7820 | 289483-69-8 | sc-507333 | 10 mg | $102.00 | ||
E7820, a fibroblast growth factor receptor (FGFR) inhibitor, indirectly activates Integrin β6. By inhibiting FGFR signaling, E7820 modulates downstream pathways, promoting Integrin β6 activation and influencing cellular processes such as angiogenesis and tissue remodeling. | ||||||
Fasentin | 392721-37-8 | sc-215012 sc-215012A | 5 mg 25 mg | $128.00 $449.00 | ||
Fasentin, a Rac1 inhibitor, indirectly activates Integrin β6. By inhibiting Rac1, Fasentin affects downstream pathways, enhancing Integrin β6 activation and influencing cellular adhesion, migration, and invasion in the context of cancer progression. | ||||||
Tanshinone IIA | 568-72-9 | sc-200932 sc-200932A | 5 mg 25 mg | $88.00 $316.00 | 22 | |
Tanshinone IIA, a STAT3 inhibitor, indirectly activates Integrin β6. By modulating STAT3 signaling, Tanshinone IIA influences downstream events, promoting Integrin β6 activation and impacting cellular processes, including inflammation and tissue repair. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid, a bisphosphonate, indirectly activates Integrin β6. Through its impact on the mevalonate pathway, Zoledronic acid modulates downstream events, leading to enhanced Integrin β6 activation and influencing cellular adhesion and migration. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271, a FAK inhibitor, indirectly activates Integrin β6. By blocking FAK signaling, PF-562271 modulates downstream pathways, promoting Integrin β6 activation and impacting cellular adhesion, migration, and invasion in various contexts, including cancer. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01, a TGF-β receptor inhibitor, indirectly activates Integrin β6. By inhibiting TGF-β signaling, A-83-01 modulates downstream events, promoting Integrin β6 activation and influencing cellular processes, particularly in the context of fibrosis and wound healing. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, indirectly activates Integrin β6. By blocking EGFR signaling, Gefitinib modulates downstream pathways, promoting Integrin β6 activation and influencing cellular adhesion and migration, particularly in the context of cancer progression. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795, an IKK inhibitor, indirectly activates Integrin β6. By blocking IKK signaling, BX-795 modulates downstream pathways, promoting Integrin β6 activation and influencing cellular adhesion, migration, and invasion, particularly in inflammatory conditions. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, indirectly activates Integrin β6. By blocking JAK signaling, Ruxolitinib modulates downstream pathways, promoting Integrin β6 activation and influencing cellular processes, particularly in the context of inflammation and fibrosis. | ||||||